ReviewHematology. American Society of Hematology. Education Program2025
When sickle cell trait is not just trait: risk of VTE.
Review in Hematology. American Society of Hematology. Education Program, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The pathophysiology of venous thromboembolism (VTE) is complex. While perturbations in the coagulation system have generally been considered the primary driver of VTE risk, there is increasing recognition that additional whole-blood components also play a crucial role in clot formation. The erythrocyte is a particularly important-and often overlooked-contributor to venous thrombi ("red clots"). Sickle cell trait (SCT), the most common hemoglobin variant worldwide, has been consistently shown to confer a modestly increased risk of VTE, and pathophysiologic studies indicate that subclinical erythrocyte changes in SCT interact both with the coagulation system and with clot composition. In this review, we characterize SCT ("HbAS" or "heterozygous HbS") as a low-risk inherited thrombophilia and compare it to the most well-known thrombophilias: heterozygous factor V Leiden and prothrombin 20210A mutation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.